Add-on Salmeterol Versus Montelukast in Arg/Arg-16 Asthmatics

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether patients with asthma who carry a genotype associated with adverse outcomes with long-acting beta-2 agonists like salmeterol show greater benefit from the use of an asthma drug that works via alternative pathways like montelukast.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Dundee
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Fluticasone; Montelukast; Salmeterol Xinafoate

Criteria

Inclusion Criteria:

All children and adolescents (5-18 years) with asthma in Tayside (Scotland) known:

• To carry the Arg/Arg-16 genotype and

• Currently on inhaled steroids and

• Inhaled bronchodilators according to need will be telephoned or contacted through home visits to establish if they have had:

• Any school absences from asthma or

• Out-of-hours visits to GP/hospital visits or admissions due to asthma over the previous 12 months.

Exclusion Criteria:

• The presence of serious respiratory or multi-system disease (e.g. cystic fibrosis, cancer under current treatment)